We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    XMT-1522
Previous Study | Return to List | Next Study

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

This study is currently recruiting participants.
Verified May 2017 by Mersana Therapeutics
Sponsor:
ClinicalTrials.gov Identifier:
NCT02952729
First Posted: November 2, 2016
Last Update Posted: May 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Mersana Therapeutics
  Purpose
This Phase 1b trial is an open label, multi-center study of XMT-1522 administered as an intravenous infusion once every three weeks. The dose escalation part of the study will establish the maximum tolerated dose or recommended Phase 2 dose for in patients with advanced breast cancer and either a HER2 immunohistochemistry (IHC) score of at least 1+ using a validated IHC assay or with evidence of HER2 amplification. Patients with HER2 positive (by IHC or amplification) gastric cancer or nonsmall cell lung cancer may also be eligible for participation in dose escalation. Upon completion of dose escalation, the cohort expansion segment of the study will consist of four parallel cohorts of different patients groups to confirm the maximum tolerated dose or the recommended Phase 2 dose and estimate the objective response in each of the patient populations.

Condition Intervention Phase
Advanced Breast Cancer Advanced Nonsmall Cell Lung Cancer Advanced Gastric Cancer Drug: XMT-1522 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Resource links provided by NLM:


Further study details as provided by Mersana Therapeutics:

Primary Outcome Measures:
  • Maximum tolerated dose or recommended Phase 2 dose [ Time Frame: Up to 14 weeks, from the date of first dose until unacceptable side effects or a dose-limiting toxicity is met. ]
    Evaluate adverse events and use of concomitant medication use after XMT-1522 doses


Secondary Outcome Measures:
  • Time of maximum observed concentration of XMT-1522 [ Time Frame: Daily for one week after first dose; weekly until 21 days after first dose; immediately before and after and 1 week after all subsequent doses ]
    Determine the pharmacokinetics of XMT-1522

  • Maximum concentration of XMT-1522 [ Time Frame: Daily for one week after first dose; weekly until 21 days after first dose; immediately before and after and 1 week after all subsequent doses ]
    Determine the pharmacokinetics of XMT-1522

  • Area under the concentration curve of the last measurable concentration of XMT-1522 [ Time Frame: Daily for one week after first dose; weekly until 21 days after first dose; immediately before and after and 1 week after all subsequent doses ]
    Determine the pharmacokinetics of XMT-1522

  • Antineoplastic effects of XMT-1522 [ Time Frame: Every 6 weeks up to 12 months ]
    Monitor tumor size

  • Anti-drug antibody [ Time Frame: Before first dose, 21 and 42 days after first dose, and every 42 days until end of study which is estimated to be 100 days (14 weeks) after first dose ]
    Analyze blood for antibodies to XMT-1522 and neutralizing antibodies


Estimated Enrollment: 120
Study Start Date: November 2016
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose Escalation and Confirmation
XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
Drug: XMT-1522
one intravenous dose administered in-clinic every 21 days

Detailed Description:

The dose escalation segment of the study utilizes a 3+3 design. Initially, 3 patients will be dosed at each dose level. The first 3-week cycle of treatment constitutes the dose limiting toxicity (DLT) evaluation period. If none of the 3 patients experience a DLT during the evaluation period and the Safety Review Committee agrees this was a reasonably well tolerated dose, 3 patients will be enrolled at the next dose level. However, in the event of 1 DLT, 3 additional patients will be enrolled at the same dose level. Any dose level with 2 or more DLTs will be considered to have exceeded the maximum tolerated dose and subsequent patients will be enrolled at lower dose levels. After the first cycle, patients may continue to receive XMT-1522 until disease progression as long as the drug is well-tolerated and patients continue to derive clinical benefit in the opinion of the Investigator.

After completion of the dose escalation, the expansion segment will enroll the patients with the following kinds of cancer:

  • Cohort 1: Advanced breast cancer, HER2 IHC 1+, or HER2 IHC 2+ without HER2 gene amplification
  • Cohort 2: Advanced breast cancer, HER2-positive, who have received prior ado-trastuzumab emtansine
  • Cohort 3: Advanced gastric cancer, HER2-positive, who have received prior trastuzumab
  • Cohort 4: Advanced non-small cell lung cancer, HER2 IHC 2+ or 3+, any HER2 gene amplification or mutation status
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able and willing to give informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Measurable disease via RECIST
  • Resolution of all toxic side effects from prior oncology treatments
  • Adequate organ function as measured by various blood parameters
  • Not pregnant or lactating, willing to prevent pregnancy while on study and for 6 months after the last dose of XMT-1522
  • Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable locally advanced disease, or metastatic disease and HER2 IHC 1+ or 2+ OR
  • Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable locally advanced disease, or metastatic disease and HER2 IHC 3+ or positive for HER2 gene amplification
  • Progressed following all standard of care therapies for advanced breast cancer. OR
  • Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and HER2 IHC 3+ or positive for HER2 gene amplification OR
  • Histologically or cytologically confirmed Stage IIIb or IV non-small cell lung cancer HER2 IHC 2+ or 3+ by local laboratory assessment.

Exclusion Criteria:

  • Major surgery, radiation therapy, or systemic anti-cancer therapy within 28 days of starting study treatment.
  • Some types of brain metastases
  • Peripheral neuropathy of Grade 2 within 3 weeks prior to the first study therapy
  • History of exposure to cumulative doxorubicin dose ≥ 360 mg/meter squared. If another anthracycline or more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/meter squared of doxorubicin
  • History of clinically significant cardiac dysfunction
  • Current known active infection with HIV, hepatitis B virus, or hepatitis C virus
  • Current severe, uncontrolled systemic disease
  • Severe dyspnea at rest, due to complications of advanced malignancy, or requiring supplementary oxygen therapy.
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome

Patients who participate in the dose escalation segment of the study cannot participate in the expansion segment of the study.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02952729


Contacts
Contact: Donna Jarlenski, MS 617-714-8214 djarlenski@mersana.com

Locations
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33607
Contact: Tiffany Romerhausen, MPH    813-745-2146    Tiffany.Romershausen@moffitt.org   
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Aditya Bardia, MD    617-724-4000    Bardia.Aditya@mgh.harvard.edu   
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: http://sarahcannon.com/searchct/results.dot         
United States, Texas
Mary Crowley Cancer Research Center Recruiting
Dallas, Texas, United States, 75230
Contact: Amy Jordan    972-566-3000    referral@marycrowley.org   
South Texas Accelerated Research Therapeutics (START) Recruiting
San Antonio, Texas, United States, 78229
Contact: Isabel Jimenez, RN, MSN    210-593-5252    isable.jimenez@start.stoh.com   
Principal Investigator: Murali Beeram, MD, MBBS         
Sponsors and Collaborators
Mersana Therapeutics
Investigators
Study Director: Donald Bergstrom, MD, PhD Mersana Therapeutics, Inc.
  More Information

Responsible Party: Mersana Therapeutics
ClinicalTrials.gov Identifier: NCT02952729     History of Changes
Other Study ID Numbers: XMT-1522-1
First Submitted: October 27, 2016
First Posted: November 2, 2016
Last Update Posted: May 9, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Breast Neoplasms
Stomach Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases